STEM CELL THERAPY FOR PARKINSON’S DISEASE: A REVIEW
The characteristic pathological features of Parkinson's disease are a reduction in neurons of pigmented brainstem nuclei, along with the presence of eosinophilic inclusion bodies, called Lewy bodies, in living cells. In Parkinson's disease,before the appearance of symptoms, there is a loss of over 80% of nigral neurons. The ‘Braak hypothesis’ has been proposed to account for the spread of pathology within the Parkinsonian brain and suggests that α-synuclein may first accumulate in the lower brainstem and then gradually arises rostrally to affect critical brain regions including the substantia nigra and ultimately the cerebral cortex (Braak et al., 2003). Dopaminergic neurons are not only cells to die within the brainstem, but an excess of other nuclei and neurotransmitter systems are involved too. For example, cholinergic neurons within the pedunculopontine nucleus degenerate, providing potential clinicopathological correlates with postural instability, swallowing difficulty (dysphagia) and sleep disturbance (REM sleep behavioral disturbance). The involvement of this nucleus in Parkinson's disease may explain why dopaminergic therapy is relatively ineffective in treating these particular clinical problems. Within the striatum, changes occur within γ-aminobutyric acid-containing neurons, as a concern of nigrostriatal dopaminergic deficiency and also an anon-physiological dopaminergic replacement. These changes are thought to play a key role in mediating the development of involuntary movements (dyskinesias) which develop after a number of years of levodopa treatment. The loss of noradrenergic and serotonergic neurons within the locus coeruleus and the raphe nucleus, correspondingly, may provide a pathophysiological basis for depression, which is common in Parkinson's disease.
STEM CELL THERAPY:
The stem cell is the techniques most useful for cure of injury or treats the disease. This type of cell is having the ability to self-renew which offers significant potential for generation of tissue that can potentially replace diseased and damaged area in the body with minimum risk of rejection and side effects. The medical researcher anticipate that adult and embryonic stem cell will soon be able to treat cancer,diabetes ,parkinsonison’s, Huntington's disease, etc. (Kalra and Tomar 2014)
Treatment of Parkinson’s by stem cell therapy:
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, which affect 1 % of the population worldwide after the period of 65 years of age. The typical symptoms of Parkinson’s disease are bradykinesia, rigidity and resting tremor(Tanner and Goldman 1996). The main pathological features are extensive loss of dopamine neurons in the Substantia Nigra pars compacta and the accumulations of cytoplasmic eosinophilic inclusions, Lewy bodies (Forno 1996). The cause of degenerated nigrostriatal dopaminergic neurons is unknown. Presently the therapy given to Parkinson’s patients include levodopa, monoamine oxidase inhibitors, dopaminergic agonists, and deep brain stimulation. Normally, the effectiveness of oral medications starts to wear off after a period of 5 years (Jankovic 2005). Moreover, these treatments cannot repair the damaged dopaminergic striatal projections; therefore, restorative approaches should be considered in order to improve the therapeutic action. Since Parkinson’s disease patients display selective degeneration of SN dopaminergic neurons, cell replacement therapies which can produce functional dopaminergic neurons may be a valuable therapeutic tactic. To achieve a successful cell-based therapy in Parkinson’s disease, some criteria for cell transplantation are generally suggested (Lindvall and Hagell 2000; Lindvall and Kokaia 2006; Lindvall et al. 2004).
The cells should possess the molecular, morphological and electrophysiological properties of dopaminergic neurons in substantia nigra;
The therapy should enable 100,000 or more DA neurons to survive long-term in human putamen;
The grafted cells should re-establish a dense terminal network throughout the striatum to functionally integrate into host neural circuitries. Here we review the progress of stem cell therapies and discuss the major problems encountered in Parkinson’s disease.
The content of graft is the serious issue when performing the transplantation. It is presently unknown whether symptomatic relief would be best achieved by implanting of DA neurons or a graft containing a portion of glial cells. During embryonic development,several studies support the necessary role of astrocytes in neural differentiation, implying that glial cells are important for fate determination of precursors during implantation (Song et al. 2002). So, mesencephalic tissues consisting glial cells were most often used in previous studies. Another key issue in performing grafts for PD treatment is that implanting the most suitable subtype of DA neurons is also critical for the result of transplantation. DA rich-ventral mesencephalic grafts contain two types of DA neuron progenitors, containing A9 Substantia Nigra neurons and A10 dopamine neurons of the Ventral Tegmental Area. The A9 subtype DA neurons only sends innervated axons into the striatum in rats suggesting that mesencephalic grafts with more A9 subtype DA neurons would be more beneficial for PD treatment. In the late 1980s, clinicians transplanted human embryonic or fetal ventral mesencephalic tissues into PD patients, but the results were varied. In Madrazo and Lindvall’s open-label trials, PD patients showed improvement of Unified Parkinson’s Disease Rating Scale (UPDRS) after receiving fetal DA neuron graft (Madrazo et al. 1988; Lindvallet al. 1989). Yet, the results from two double-blind trials funded by the National Institutes of Health (NIH) in the 1990s showed no major effects (Freed et al. 2001; Olanow et al. 2003). Even more, several side-effects have been shown in PD patients who received these transplantations. The results of these two open-label and double-blind trials raise critical issues regarding ethical considerations and may enhance controversy which can dissuade the potential use of transplants for PD.
ES cell‑derived DA neurons ES cells are one important source that has been used to differentiate into DA neurons in the laboratory. DA neurons derived from rodents and humans have been shown to survive and function after transplantation into the striatum of PD rats (Kim et al. 2002; Yang et al. 2008). Furthermore, the uptake of [18F]-DOPA also increased 14 weeks after transplantation, suggesting exogenous ES cell-derived DA neurons could offer the functional recovery of DA neurons. Until now, ES cells are still the most promising source to differentiate into DA neurons (Kim et al. 2002; Rodriguez Gomez et al. 2007); however, the efficiency to differentiate into DA neurons and the existence rate of these neurons after transplantation is still low. For example, prior reports showed less than 300 tyrosine hydroxylase (TH)-positive neurons survived after transplanting 100,000–400,000 ES cells into the striatum (Brederlau et al. 2006; Ben-Hur et al. 2004). Therefore a critical issue that must be resolved to enhance recovery after transplantation in PD is an improvement of the differentiation and survival rate (Bergman and Deuschl 2002)
iPSC-derived DA neurons:
Subsequently, the iPSC technique was recognized in 2006, another cell source to generate DA neurons was provided. At first, in 2008, the DA neurons were made from mouse into the striatum of a rat Parkinson’s Disease model, thereby easing the symptoms of Parkinson’s Disease. In 2010, DA neurons differentiated from ipscsofParkinson’s Disease patients were transplanted into Parkinson’s Disease transgenic rats, and these neurons survived for some months and further eased the symptoms of Parkinson’s Disease(Hargus et al. 2010). These transplanted cells did not display α-synuclein positive inserts bodies in hosts, signifying that in Parkinson’s Disease patients may be a viable option. However, several reports have mentioned patient-derived ips are still more vulnerable to Parkinson’s Disease because of mutations or epigenetic markers in cells (Badger et al. 2014; Beevers et al. 2013; Sanchez-Danes et al. 2012). Furthermore, the risk of tumor formation still needs to be reduced before the medical application can be understood (Petit et al. 2014). Since the method of iPSC production was only developed a few years ago, further optimization may overcome these problems.
Nscsand NSC derived DA neurons nscsare multipotent stem cells that are defined as “neurally” designed cells and retain their regional specificity (Horiguchi et al. 2004). Therefore, NPCs that are derived from a chiefly DA vicinity, such as ventral mesencephalon (VM), should be the most suitable source of DA neurons. Several reports have shown the potential skill of nscsto differentiate into DA neurons (Tan et al. 2014, 2015), and also established the advances of symptoms in Parkinson’s Disease models after transplantation of NSC-derived DA neurons (Parish et al. 2008; Redmond et al. 2007). Furthermore, overexpression of different genetic factor, such as Lmx1a, glial cell line-derived neurotrophic factor (GDNF), Brn4 and TH, in nscshasimproved the valuable effects of NSC-derived DA neurons (Tan et al. 2014; Wu et al. 2015; Wakeman et al. 2014). In animal studies, NSC-derived DA neurons overexpressing Nurr1, a critical factor involved in DA requirement and survival, has led to functional improvement in rats treated with 6-hydroxydopamine (6-OHDA), a toxic-induced Parkinson’disease model (Park et al. 2006). However, the survival rate of TH positive neurons after a replacement was less than 4.3 % (Park et al. 2006; Studer et al. 1998). In 2008, Parish et al. Transfected Wnt5a into nscs from mouse VM, generating tenfold more DA neurons with TH positive signal than the conventional FGF2-treated nscs from VM and causing a functional recovery in 6-OHDA mice (Parish et al. 2008). Aside from VM, investigators have also derived nscs from the SVZ, which is another well-known source for these cells. The auxiliary of nscs from SVZ boosted the recovery of Parkinson’s Disease symptoms, but the survival rate of these cells was still low (Meissner et al. 2005; Richardson et al. 2005). Therefore, the most important matter that must be overcome in order to achieve NSCrelocation is to increase the cell number and existence rate of transplanted cells.
Although the brain is considered as an immune-privileged site, the host immune system still responds to the grafts. The interaction between implantation and the endogenous immune system affects the survival of grafted cells. In several clinical trials, transplantation without adequate immune-suppression may have led to poor outcomes (Freed et al. 2001; Olanow et al. 2003), while transplantation with an immune-suppressant, such as cyclosporine, azathioprine,and prednisolone, produced better effects (Lindvall et al. 1989). Unfortunately, patient symptoms worsened after withdrawal of immune-suppression, and postmortem showed grafts were surrounded by activated microglia and immune reactivity (Olanow et al. 2003). These results imply that immune reactions exert a negative effect during transplantation, and it would be necessary to use an immunosuppressant in combination with grafting; however, further studies are still needed to determine the optimal immunosuppressant and the period of treatment.
MAJOR DISPUTES AFTER GRAFTS:
Depending on the reports of several cell-based studies in both animals and humans, there are two major apprehensions related to grafts.
Graft Induced Dyskinesia (GID)
The occurrence of dyskinesia after transplantation was first reported by Defer et al. (1996), but did not obtain much courtesy till Freed’s trial in 2001 (Freed et al. 2001). They described the development of “graft persuaded dyskinesia (GID)” in 15 % of transplanted patients 1 year after transplantation. This surprising symptom reached 56 % in Olanow’s study (Olanow et al. 2003). It is speculated that the number of grafted cells used in the surgery-controlled clinical trials was less than those of other more successful studies (Lindvall et al. 1989; Freed et al. 2001). Furthermore, immune-suppression may be also an important aspect since dyskinesia did not develop till immunosuppression withdrawal in several reports (Olanow et al. 2003; Piccini et al. 2005; Lane et al. 2008). The other possible dispute is that other varied grafts were originated in ventral putamen, containing serotonergic neurons. These grafts led to islands of reinnervation and abnormal production of DA (Ma et al. 2002; Carlsson et al. 2009). Hence, transplanting a sufficient number of cells having a pure population of DA neurons in basal ganglion with immunosuppression is suggested to avoid the progress of GID.
Grafts affected by PD process:
Indications that PD pathology may propagate from host to grafts is emerging (Kordower et al. 2008a, b; Li et al. 2008). The presence of LBs and Lewy neurites in grafted DA neurons were generally observed 11–16 years after human fetal mesencephalic transplantation (Kordower et al. 2008a, b; Li et al. 2008; however,α-synucleinstaining is generally not detectable in adults younger than 20-year-old (the Chu and Kordower 2010). These observations imply that PD pathology can be transferred from host to graft (Visanji et al. 2013). The exact reasons for this negative outcome remain unresolved. A recent report showed that fetal cell transplantation in two PD patients remains highly functional even 15–18 years after surgery (Kefalopoulou et al. 2014). Therefore, although the spread of PD pathology may occur after transplantation, the period of beneficial effects from transplantation is still longer than that of current medications, suggesting stem cells still could be a potential clinical therapy (Rana, 2011).
NOW YOU CAN ALSO PUBLISH YOUR ARTICLE ONLINE.
SUBMIT YOUR ARTICLE/PROJECT AT email@example.com
FIND OUT MORE ARTICLES AT OUR DATABASE